Benitec Biopharma Inc. (BNTC) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 6 Buy, 1 Hold.
The consensus price target is $27.00 (low: $22.00, high: $32.00), representing an upside of 103.8% from the current price $13.25.
Analysts estimate Earnings Per Share (EPS) of $-4.79 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.68 vs est $-4.79 (beat +44.1%). 2025: actual $-1.05 vs est $-1.25 (beat +15.8%). Analyst accuracy: 51%.
BNTC Stock — 12-Month Price Forecast
$27.00
▲ +103.77% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Benitec Biopharma Inc., the average price target is $27.00, with a high forecast of $32.00, and a low forecast of $22.00.
The average price target represents a +103.77% change from the last price of $13.25.
Highest Price Target
$32.00
Average Price Target
$27.00
Lowest Price Target
$22.00
BNTC Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Benitec Biopharma Inc. in the past 3 months
EPS Estimates — BNTC
51%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.68
vs Est –$4.79
▲ 78.7% off
2025
Actual –$1.05
vs Est –$1.25
▲ 18.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — BNTC
46%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 53.7% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
